Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

5.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Respiratory rate and minute ventilation independently modulate cardiovascular and autonomic responses in healthy adults.

Scientific reports·2026
Same author

Molecular evolution and antigenic stability of ibaraki virus: evidence for regional circulation from a South Korean whole-genome analysis.

Scientific reports·2026
Same author

Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer.

Cancer research and treatment·2026
Same author

Effects of non-invasive trigeminal nerve stimulation frequency and duration on cardiovascular responses.

Biomedical engineering letters·2026
Same author

Exploring Age-Related Patterns in Smartphone Keystroke Dynamics Considering Temporal Variability: Cross-Sectional Study With AI-Based Analysis.

JMIR mHealth and uHealth·2025
Same author

Turing-Type Catalytic 2D-Metal Nanomesh Inside Silica-Bilayer for Multicomponent Reaction Control.

Journal of the American Chemical Society·2025

Related Experiment Video

Updated: Jun 6, 2025

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
09:31

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model

Published on: November 9, 2018

8.6K

Gossypetin Alleviates DSS-induced Colitis by Regulating COX2 and ROS-JNK Signaling.

Hyeonjin Kim1, Eungyung Kim1, Lei Ma1

  • 1Department of Animal Science and Biotechnology, Research Institute for Innovative Animal Science, Kyungpook National University, Sangju-si, Gyeongsang buk-do, Republic of Korea, Daegu, South Korea.

Current Pharmaceutical Biotechnology
|November 27, 2024
PubMed
Summary

Gossypetin, a natural flavonoid, effectively reduced inflammation and tissue damage in a colitis model. This compound shows promise for treating Inflammatory Bowel Disease (IBD) with fewer side effects.

Keywords:
Anti-inflammationDSS-induced colitisanti-oxidantgossypetininflammatory bowel diseasetherapeutic potential.

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.2K
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
08:39

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Published on: January 19, 2010

49.8K

Related Experiment Videos

Last Updated: Jun 6, 2025

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
09:31

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model

Published on: November 9, 2018

8.6K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.2K
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
08:39

Murine Colitis Modeling using Dextran Sulfate Sodium DSS

Published on: January 19, 2010

49.8K

Area of Science:

  • Gastroenterology and Immunology
  • Natural Product Chemistry
  • Pharmacology

Background:

  • Inflammatory Bowel Disease (IBD) is a chronic gastrointestinal condition with increasing global incidence.
  • Current treatments like surgery and drugs have limitations, including invasiveness and side effects.
  • Gossypetin, a flavonoid from plants like hibiscus, has known antioxidant and anticancer properties, but its effect on IBD is unknown.

Purpose of the Study:

  • To investigate the therapeutic potential of gossypetin in a colitis model.
  • To evaluate gossypetin's efficacy in mitigating IBD symptoms and underlying pathological processes.

Main Methods:

  • Utilized a Dextran Sodium Sulfate (DSS)-induced colitis mouse model.
  • Assessed therapeutic efficacy using Disease Activity Index (DAI) scores and histological analysis.
  • Measured inflammatory cytokines, Superoxide Dismutase (SOD), tight junction markers, COX-2, and JNK signaling via qRT-PCR, immunohistochemistry, and Western blot.

Main Results:

  • Gossypetin treatment ameliorated DSS-induced weight loss and reduced colon damage.
  • Gossypetin significantly decreased DAI scores and histological signs of colitis.
  • Treatment increased tight junction expression, reduced inflammation, reactive oxygen species (ROS), JNK signaling, and apoptosis.

Conclusions:

  • Gossypetin demonstrates significant therapeutic potential for colitis by targeting ROS-JNK signaling pathways.
  • This natural compound may offer a promising alternative for IBD treatment with improved efficacy and reduced side effects.
  • Highlights the potential of natural compounds in developing targeted therapies for inflammatory conditions.